NCT04889651View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

June 8, 2021

Study Completion Date

June 22, 2021

Conditions
Prostate Cancer
Interventions
DRUG

BR9004

BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.

DRUG

BR9004-1

BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea

Trial Locations (1)

13520

CHA Bundang Medical Center, CHA University, Gyeonggi-do

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY